Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique

Imagem de Miniatura
Arquivos
art_ORFALI_Consensus_on_the_therapeutic_management_of_atopic_dermatitis_2023.PDF (2.95 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
LORENZINI, Daniel
BRESSAN, Aline
TANAKA, Anber Ancel
CERQUEIRA, Ana Maria Mosca de
RAMOS, Andrea Machado Coelho
PROENCA, Carolina Contin
SILVA, Claudia Marcia de Resende
LACZYNSKI, Cristina Marta Maria
Citação
ANAIS BRASILEIROS DE DERMATOLOGIA, v.98, n.6, p.814-836, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
This publication is an update of the ""Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology"" published in 2019, considering the novel, targeted-oriented systemic therapies for atopic dermatitis. The initial recommendations of the current consensus for systemic treatment of patients with atopic dermatitis were based on a recent review of scientific published data and a consensus was reached after voting. The Brazilian Society of Dermatology invited 31 experts from all regions of Brazil and 2 international experts on atopic dermatitis who fully contributed to the process. The methods included an e-Delphi study to avoid bias, a literature search and a final consensus meeting. The authors added novel approved drugs in Brazil and the indication for phototherapy and systemic therapy for AD. The therapeutical response to systemic treatment is hereby reported in a suitable form for clinical practice and is also part of this updated manuscript. (c) 2023 Sociedade Brasileira de Dermatologia.
Palavras-chave
Atopic dermatitis, Delphi technique, Medication therapy management, Phototherapy
URI
https://observatorio.fm.usp.br/handle/OPI/57389
Referências
  1. accessdata.fda, Abrocitinib FDA approval for adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe AD 2023
  2. Affleck A, 2019, CLIN EXP DERMATOL, V44, P591, DOI 10.1111/ced.13972
  3. Agencia Nacional de Vigilancia Sanitaria-Anvisa, US
  4. Akinlade B, 2019, BRIT J DERMATOL, V181, P459, DOI 10.1111/bjd.17869
  5. AlJohani NI, 2021, HEMATOLOGY, V26, P620, DOI 10.1080/16078454.2021.1966222
  6. Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051
  7. [Anonymous], Manual Pratico de Fototerapia 2020
  8. Aoki V, 2019, AN BRAS DERMATOL, V94, pS67, DOI 10.1590/abd1806-4841.2019940210
  9. Arnone M, 2019, AN BRAS DERMATOL, V94, pS76, DOI 10.1590/abd1806-4841.2019940211
  10. Avery Anthony J, 2005, Inform Prim Care, V13, P3
  11. Bedoui Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205023
  12. Sawangjit R, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013206.pub2
  13. Schünemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE
  14. Shea B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000951.pub2
  15. Shi VY, 2022, J AM ACAD DERMATOL, V87, P351, DOI 10.1016/j.jaad.2022.04.009
  16. Siegels D, 2021, ALLERGY, V76, P1053, DOI 10.1111/all.14631
  17. Silverberg JI, 2021, J EUR ACAD DERMATOL, V35, P1797, DOI 10.1111/jdv.17351
  18. Silverberg JI, 2021, BRIT J DERMATOL, V184, P450, DOI 10.1111/bjd.19573
  19. Silverberg JI, 2020, JAMA DERMATOL, V156, P863, DOI 10.1001/jamadermatol.2020.1406
  20. Silverberg JI, 2018, ANN ALLERG ASTHMA IM, V121, P604, DOI 10.1016/j.anai.2018.07.042
  21. Simpson EL, 2020, BRIT J DERMATOL, V183, P242, DOI 10.1111/bjd.18898
  22. van der Schaft J, 2015, BRIT J DERMATOL, V172, P1621, DOI 10.1111/bjd.13730
  23. Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020
  24. Simpson EL, 2022, JAMA DERMATOL, V158, P404, DOI 10.1001/jamadermatol.2022.0029
  25. Simpson EL, 2020, LANCET, V396, P255, DOI 10.1016/S0140-6736(20)30732-7
  26. Simpson EL, 2020, JAMA DERMATOL, V156, P44, DOI 10.1001/jamadermatol.2019.3336
  27. Simpson EL, 2017, J AM ACAD DERMATOL, V77, P623, DOI 10.1016/j.jaad.2017.06.042
  28. Vakharia PP, 2018, AM J CLIN DERMATOL, V19, P15, DOI 10.1007/s40257-017-0299-4
  29. Van der Schaft J, 2015, ACTA DERM-VENEREOL, V95, P963, DOI 10.2340/00015555-2125
  30. VENKATARAMANAN R, 1985, TRANSPLANT P, V17, P286
  31. Vermeulen FM, 2020, BRIT J DERMATOL, V183, P1073, DOI 10.1111/bjd.18959
  32. Vestergaard C, 2020, J EUR ACAD DERMATOL, V34, P426, DOI 10.1111/jdv.16171
  33. Vincent R, 2020, BRIT J DERMATOL, V183, P566, DOI 10.1111/bjd.19030
  34. Werfel T, 2021, J DTSCH DERMATOL GES, V19, P151, DOI 10.1111/ddg.14371
  35. WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x
  36. Williams HC, 2022, J ALLERGY CLIN IMMUN, V149, P1899, DOI 10.1016/j.jaci.2022.03.017
  37. Wollenberg A, 2022, J EUR ACAD DERMATOL, V36, P1904, DOI 10.1111/jdv.18429
  38. Ben Mordehai Y, 2022, DERMATITIS, V33, P282, DOI 10.1097/DER.0000000000000810
  39. Wollenberg A, 2022, J EUR ACAD DERMATOL, V36, P1409, DOI 10.1111/jdv.18345
  40. Wollenberg A, 2021, BRIT J DERMATOL, V184, P437, DOI 10.1111/bjd.19574
  41. Wollenberg A, 2018, J ALLER CL IMM-PRACT, V6, P1778, DOI 10.1016/j.jaip.2018.01.034
  42. Xiao H, 2022, PHOTODERMATOL PHOTO, V38, P233, DOI 10.1111/phpp.12741
  43. Yilmaz DE, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101589
  44. Yu SH, 2018, J AM ACAD DERMATOL, V78, P733, DOI 10.1016/j.jaad.2017.09.074
  45. Bieber T, 2022, J EUR ACAD DERMATOL, V36, P1432, DOI 10.1111/jdv.18225
  46. Bieber T, 2023, J DERMATOL TREAT, V34, DOI 10.1080/09546634.2022.2161812
  47. Bieber T, 2021, NEW ENGL J MED, V384, P1101, DOI 10.1056/NEJMoa2019380
  48. Blauvelt A, 2022, BRIT J DERMATOL, V186, pE142
  49. Blauvelt Andrew, 2022, J Am Acad Dermatol, V86, P104, DOI 10.1016/j.jaad.2021.05.075
  50. Blauvelt A, 2021, JAMA DERMATOL, V157, P1047, DOI 10.1001/jamadermatol.2021.3023
  51. Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1
  52. Bressan AL, 2010, AN BRAS DERMATOL, V85, P9, DOI 10.1590/S0365-05962010000100002
  53. Campanati A, 2022, ARCH DERMATOL RES, V314, P593, DOI 10.1007/s00403-021-02243-w
  54. Choi JY, 2021, CLIN EXP DERMATOL, V46, P1067, DOI 10.1111/ced.14676
  55. Chovatiya R, 2021, J ALLERGY CLIN IMMUN, V148, P927, DOI 10.1016/j.jaci.2021.08.009
  56. consultas.anvisa, Consultas. Anvisa-Agencia Nacional de Vigilancia Sanitaria
  57. Davis DMR, 2022, J AM ACAD DERMATOL, V86, P1335, DOI 10.1016/j.jaad.2022.01.009
  58. Dayal S, 2017, AN BRAS DERMATOL, V92, P801
  59. de Bruin-Weller M, 2018, BRIT J DERMATOL, V178, P1083, DOI 10.1111/bjd.16156
  60. De Bruin-Weller M, 2021, ACTA DERM-VENEREOL, V101, DOI 10.2340/00015555-3751
  61. De Villiers MR, 2005, MED TEACH, V27, P639, DOI 10.1080/13611260500069947
  62. Deeks ED, 2021, DRUGS, V81, P2149, DOI 10.1007/s40265-021-01638-3
  63. Diani M, 2016, GIORN ITAL DERMAT V, V151, P535
  64. Drucker AM, 2022, DERMATITIS, V33, P200, DOI 10.1097/DER.0000000000000845
  65. Drucker AM, 2022, JAMA DERMATOL, V158, P523, DOI 10.1001/jamadermatol.2022.0455
  66. Drucker AM, 2020, JAMA DERMATOL, V156, P659, DOI 10.1001/jamadermatol.2020.0796
  67. Duggan S, 2021, DRUGS, V81, P1657, DOI 10.1007/s40265-021-01583-1
  68. Eichenfield LF, 2021, JAMA DERMATOL, V157, P1165, DOI 10.1001/jamadermatol.2021.2830
  69. Ferreira S, 2020, AM J CLIN DERMATOL, V21, P783, DOI 10.1007/s40257-020-00548-6
  70. FERRINI S, 1986, CLIN IMMUNOL IMMUNOP, V38, P79, DOI 10.1016/0090-1229(86)90124-8
  71. Freitas Thais Helena Proença de, 2007, An. Bras. Dermatol., V82, P63, DOI 10.1590/S0365-05962007000100009
  72. Garritsen FM, 2014, BRIT J DERMATOL, V170, P501, DOI 10.1111/bjd.12645
  73. Gerbens LAA, 2018, BRIT J DERMATOL, V178, P1288, DOI 10.1111/bjd.16240
  74. Gilaberte Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061632
  75. Gooderham MJ, 2019, JAMA DERMATOL, V155, P1371, DOI 10.1001/jamadermatol.2019.2855
  76. gov.br, Agencia Nacional de Vigilancia Sanitaria--Anvisa. Dupixent (dupilumabe): nova indicacao
  77. gov.br, Brasil. Ministerio da Saude. Agencia Nacional de Vigilancia Sanitaria-Anvisa. Olumiant® (Baricitinibe): nova indicacao
  78. Grim J, 2003, CLIN PHARMACOKINET, V42, P139, DOI 10.2165/00003088-200342020-00003
  79. Guttman-Yassky E, 2021, LANCET, V397, P2151, DOI 10.1016/S0140-6736(21)00588-2
  80. Guttman-Yassky E, 2020, J ALLERGY CLIN IMMUN, V145, P877, DOI 10.1016/j.jaci.2019.11.025
  81. Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE
  82. HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44
  83. Harper JI, 2000, BRIT J DERMATOL, V142, P52, DOI 10.1046/j.1365-2133.2000.03241.x
  84. Hoare C, 2000, Health Technol Assess, V4, P1
  85. Holliday Alex C, 2013, Skin Therapy Lett, V18, P4
  86. Hollywood A, 2020, BRIT J DERMATOL, V182, P1290, DOI 10.1111/bjd.18698
  87. homeforeczema.org, UK: Harmonizing Outcome Measures for Eczema (HOME)
  88. Hoy SM, 2022, AM J CLIN DERMATOL, V23, P409, DOI 10.1007/s40257-022-00684-1
  89. Jackson S, 2007, DERMATOL THER, V20, P187, DOI 10.1111/j.1529-8019.2007.00133.x
  90. Jaworek A, 2020, ACTA DERM-VENEREOL, V100, DOI 10.2340/00015555-3652
  91. Jünger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685
  92. Kalb RE, 2009, J AM ACAD DERMATOL, V60, P824, DOI 10.1016/j.jaad.2008.11.906
  93. Kamal MA, 2021, CLIN PHARMACOL THER, V110, P1318, DOI 10.1002/cpt.2366
  94. Kemény L, 2019, EXPERT REV CLIN IMMU, V15, P1205, DOI 10.1080/1744666X.2020.1672537
  95. Kreeshan FC, 2021, DERMATOLOGY THER, V11, P149, DOI 10.1007/s13555-020-00469-6
  96. Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564
  97. Li ZY, 2020, CLIN PHARM DRUG DEV, V9, P742, DOI 10.1002/cpdd.798
  98. Majoie IML, 2009, J AM ACAD DERMATOL, V60, P77, DOI 10.1016/j.jaad.2008.08.048
  99. Maksimovic V, 2020, MOL BIOL REP, V47, P4699, DOI 10.1007/s11033-020-05481-9
  100. Megna M, 2017, DERMATOLOGY THER, V7, P1, DOI 10.1007/s13555-016-0170-1
  101. Musters AH, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013870.pub2
  102. Nakashima C, 2022, ALLERGOL INT, V71, P40, DOI 10.1016/j.alit.2021.10.004
  103. Pacifico A, 2019, J EUR ACAD DERMATOL, V33, P718, DOI 10.1111/jdv.15362
  104. Paller AS, 2023, PEDIATR DRUGS, V25, P67, DOI 10.1007/s40272-022-00553-8
  105. Paller AS, 2022, LANCET, V400, P908, DOI 10.1016/S0140-6736(22)01539-2
  106. Paller AS, 2020, J AM ACAD DERMATOL, V83, P1282, DOI 10.1016/j.jaad.2020.06.054
  107. Patrizi A, 2015, CLIN COSMET INVESTI, V8, P511, DOI 10.2147/CCID.S87987
  108. Perez HC, 2017, INT J DERMATOL, V56, P370, DOI 10.1111/ijd.13409
  109. Popovic B, 2017, J MOL BIOL, V429, P208, DOI 10.1016/j.jmb.2016.12.005
  110. Pradhan S, 2019, INDIAN DERMATOL ONL, V10, P64, DOI 10.4103/idoj.IDOJ_157_18
  111. Raaby L, 2017, ACTA DERM-VENEREOL, V97, P426, DOI 10.2340/00015555-2599
  112. Reich K, 2022, J DERMATOL TREAT, V33, P1521, DOI 10.1080/09546634.2020.1839008
  113. Reich K, 2021, LANCET, V397, P2169, DOI 10.1016/S0140-6736(21)00589-4
  114. Reynolds NJ, 2001, LANCET, V357, P2012, DOI 10.1016/S0140-6736(00)05114-X
  115. Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
  116. Samorano LP, 2021, J DTSCH DERMATOL GES, V19, P294, DOI 10.1111/ddg.14414

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56